Immunwork Announces Positive Phase I Top-Line Data for TE-8214, a Long-Acting Octreotide, Demonstrating Favorable Safety, Tolerability, and Potent IGF-1 Suppression
2025/07
01
T-E Meds and Asymchem Join Forces to Drive Innovation in Drug Conjugates and Explore the Future of Targeted Therapeutics
2025/06
25
【Reported by Taiwan Global Bio Monthly】The President, Dr. Tse-Wen Chang was invited as a keynote speaker at Biologics World Taiwan 2025
2025/03
27
Our latest research result is published in J. Med. Chem.
2025/03
06
Immunwork 2025 Investor Meeting – Results Presentation
2025/01
15